Download PDF
Z Gastroenterol 2015; 53(8): 1027-1033
DOI: 10.1055/s-0034-1397882
Mitteilungen
© Georg Thieme Verlag KG Stuttgart · New York

Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Eligustat – Nutzenbewertung gemäß § 35a SGB V des G-BA

Further Information

Publication History

Publication Date:
26 August 2015 (online)

Also available at
    Permissions and Reprints

Prof. Dr. med. Claus Niederau, Oberhausen

 

  • Literaturverzeichnis

  • 1 Niederau C, Haeussinger D. Gaucher's disease: a review for the internist and hepatologist. Hepatogastroenterology 2000; 47: 984-997
    PubMedGoogle Scholar
  • 2 Giraldo P, Pocovi M, Perez-Calvo J et al. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Haematologica 2000; 85: 792-799
    PubMedGoogle Scholar
  • 3 Pastores GM, Weinreb NJ, Aerts H et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41: 4-14
    PubMedGoogle Scholar
  • 4 Beck M, vom Dahl S, Mengel E et al. Leitlinien zu Morbus Gaucher 2006 [updated 09.06.2011]. Available from: http://www.morbus-gaucher-oegg.at/wp-content/uploads/gen_leitlinien.pdf
    PubMedGoogle Scholar
  • 5 Ida H, Rennert OM, Ito T et al. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells Mol Dis 1998; 24: 73-81
    CrossrefPubMedGoogle Scholar
  • 6 Kaplan P, Andersson HC, Kacena KA et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006; 160: 603-608
    CrossrefPubMedGoogle Scholar
  • 7 Kauli R, Zaizov R, Lazar L et al. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and / or enzyme replacement therapy. Isr Med Assoc J 2000; 2: 158-163
    PubMedGoogle Scholar
  • 8 Mistry PK, Deegan P, Vellodi A et al. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol 2009; 147: 561-570
    CrossrefPubMedGoogle Scholar
  • 9 Stirnemann J, Vigan M, Hamroun D et al. The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis 2012; 7: 77
    CrossrefPubMedGoogle Scholar
  • 10 Taddei TH, Kacena KA, Yang M et al. The under-recognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009; 84: 208-214
    CrossrefPubMedGoogle Scholar
  • 11 Weinreb NJ, Goldblatt J, Villalobos J et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2013; 36: 543-553
    CrossrefPubMedGoogle Scholar
  • 12 Mistry PK, Taddei T, vom Dahl S et al. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog 2013; 18: 235-246
    CrossrefPubMedGoogle Scholar
  • 13 vom Dahl S, Niederau C, Haussinger D. Loss of vision in Gaucher's disease and its reversal by enzyme replacement therapy [letter]. N Engl J Med 1998; 338: 1471-1472
    CrossrefPubMedGoogle Scholar
  • 14 Cox TM, Rosenbloom BE, Barker RA. Gaucher disease and comorbidities: B-cell malignancy and parkinsonism. Am J Hematol 2015; 90: S25-S28
    CrossrefPubMedGoogle Scholar
  • 15 Pandey MK, Grabowski GA. Immunological cells and functions in Gaucher disease. Crit Rev Oncog 2013; 18: 197-220
    CrossrefPubMedGoogle Scholar
  • 16 Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M et al. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis 2000; 23: 77-82
    CrossrefPubMedGoogle Scholar
  • 17 Charrow J, Andersson HC, Kaplan P et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160: 2835-2843
    CrossrefPubMedGoogle Scholar
  • 18 European Medicines Agency. Cerdelga (Eliglustat) – Assessment report for an initial marketing authorisation application – Procedure No. EMEA / H/C/003724 2014 [updated 20.11.2014]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003724/WC500182389.pdf
    PubMedGoogle Scholar
  • 19 Cox TM, Drelichman G, Cravo R et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet 2015; 385: 2355-2362
    CrossrefPubMedGoogle Scholar
  • 20 Kamath RS, Lukina E, Watman N et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol 2014; 43: 1353-1360
    CrossrefPubMedGoogle Scholar
  • 21 Lukina E, Watman N, Arreguin EA et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 2010; 116: 893-899
    CrossrefPubMedGoogle Scholar
  • 22 Lukina E, Watman N, Arreguin EA et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010; 116: 4095-4098
    CrossrefPubMedGoogle Scholar
  • 23 Lukina E, Watman N, Dragosky M et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 2014; 53: 274-276
    CrossrefPubMedGoogle Scholar
  • 24 Mistry PK, Lukina E, Ben Turkia H et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA 2015; 313: 695-706
    CrossrefPubMedGoogle Scholar
  • 25 Niederau C, Rolfs A, vom Dahl S et al. [Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000]. Medizinische Klinik 2001; 96: 32-39
    PubMedGoogle Scholar
  • 26 vom Dahl S, Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Pract Res Clin Gastroenterol 2010; 24: 619-628
    CrossrefPubMedGoogle Scholar
  • 27 Salky B, Kreel I, Gelernt I et al. Splenectomy for Gaucher's disease. Ann Surg 1979; 190: 592-594
    CrossrefPubMedGoogle Scholar
  • 28 Goldblatt J. Type I Gaucher disease. J Med Genet 1988; 25: 415-418
    CrossrefPubMedGoogle Scholar
  • 29 Shiloni E, Bitran D, Rachmilewitz M et al. The role of splenectomy in Gaucher's disease. Arch Surg 1983; 118: 929-932
    CrossrefPubMedGoogle Scholar
  • 30 Rosenthal DI, Doppelt SH, Mankin HJ et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 1995; 96: 629-637
    PubMedGoogle Scholar
  • 31 Hollak CEM, Maas M, Akkerman E et al. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 2001; 27: 1005-1012
    CrossrefPubMedGoogle Scholar
  • 32 Maas M, Hollak CEM, Akkerman EM et al. Quantification of skeletal involvement in adults with type I Gaucher's disease: Fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. American Journal of Roentgenology 2002; 179: 961-965
    CrossrefPubMedGoogle Scholar
  • 33 Poll LW, Koch JA, vom Dahl S et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol 2001; 30: 496-503
    CrossrefPubMedGoogle Scholar
  • 34 Lebel E, Dweck A, Foldes AJ et al. Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 2004; 22: 597-601
    CrossrefPubMedGoogle Scholar
  • 35 de Fost M, Hollak CE, Groener JE et al., editors. Superior effects of high dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a two center retrospective analysis [abstract]. European Hematology Association; 2006 Amsterdam, The Netherlands.
    PubMedGoogle Scholar
  • 36 Poll LW, Koch JA, Willers R et al. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (Type 1) Gaucher disease in 30 adult patients. Blood Cells Mol Dis 2002; 28: 209-220
    CrossrefPubMedGoogle Scholar
  • 37 Poll LW, Maas M, Terk MR et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol 2002; 75: A25-A36
    CrossrefPubMedGoogle Scholar
  • 38 vom Dahl S, Poll L, Di Rocco M et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher disease patients. Curr Med Res Opin 2006; 22: 1045-1064
    CrossrefPubMedGoogle Scholar
  • 39 Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470
    CrossrefPubMedGoogle Scholar
  • 40 Cox T, Lachmann R, Hollak C et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-1485
    CrossrefPubMedGoogle Scholar
  • 41 Gonzalez DE, Turkia HB, Lukina EA et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol 2013; 88: 166-171
    CrossrefPubMedGoogle Scholar
  • 42 Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995; 122: 33-39
    CrossrefPubMedGoogle Scholar
  • 43 Heitner R, Elstein D, Aerts J et al. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002; 28: 127-133
    CrossrefPubMedGoogle Scholar
  • 44 Zimran A, Brill-Almon E, Chertkoff R et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011; 118: 5767-5773
    CrossrefPubMedGoogle Scholar
  • 45 Niederau C, Poll L, vom Dahl S et al. The spleen in Gaucher disease. Gaucher Clinical Perspectives: Molecular Medicine & Therapeutics 2001; 9: 14-23
    PubMedGoogle Scholar
  • 46 Weinreb NJ, Deegan P, Kacena KA et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83: 896-900
    CrossrefPubMedGoogle Scholar
  • 47 Stirnemann J, Belmatoug N, Vincent C et al. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Arthritis Res Ther 2010; 12: R156
    CrossrefPubMedGoogle Scholar
  • 48 van Dussen L, Biegstraaten M, Dijkgraaf MG et al. Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet J Rare Dis 2014; 9: 112
    CrossrefPubMedGoogle Scholar
  • 49 FDA. Center for drug evaluation and research application number: 205494Orig1s000 2014.
    PubMedGoogle Scholar
  • 50 Belmatoug N, De Villemeur TB. Skeletal response to enzyme replacement therapy for type 1 Gaucher disease: A preliminary report of the French experience. Seminars in Hematology 1995; 32: 33-38
    PubMedGoogle Scholar
  • 51 Charrow J, Dulisse B, Grabowski G et al. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007; 71: 205-211
    CrossrefPubMedGoogle Scholar
  • 52 Deegan PB, Pavlova E, Tindall J et al. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore) 2011; 90: 52-60
    CrossrefPubMedGoogle Scholar
  • 53 El-Beshlawy A, Ragab L, Youssry I et al. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 2006; 29: 92-98
    CrossrefPubMedGoogle Scholar
  • 54 Elstein D, Hadas-Halpern I, Itzchaki M et al. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis 1996; 22: 104-111
    CrossrefPubMedGoogle Scholar
  • 55 Piran S, Amato D. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J Inherit Metab Dis [Epub ahead of print] 25.03.2010; PubMed PMID: 20 336 376.
    PubMedGoogle Scholar
  • 56 Maas M, van Kuijk C, Stoker J et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging – initial experience. Radiology 2003; 229: 554-561
    CrossrefPubMedGoogle Scholar
  • 57 Mistry PK, Cappellini MD, Lukina E. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol [Epub ahead of print] 23.09.2010; PubMed PMID: 21080341.
    PubMedGoogle Scholar
  • 58 Genzyme Europe BV. Cerdelga® 84 mg (Eliglustat); Fachinformation. 2015
    PubMed
  • 59 Actelion Registration Ltd. Zavesca® (Miglustat); Fachinformation 2002
    PubMed
  • 60 Genzyme Europe BV. Cerezyme® (Imiglucerase); Fachinformation. 1997
    PubMed
  • 61 Niederau C. Neue Behandlungsstrategien der Gaucherkrankheit: Substrathemmung durch Miglustat (Zavesca). Arneimittel-, Therapie-Kritik 2004; 4: 839-849
    PubMedGoogle Scholar
  • 62 Andersson U, Butters TD, Dwek RA et al. N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 2000; 59: 821-829
    CrossrefPubMedGoogle Scholar
  • 63 Platt FM, Neises GR, Karlsson GB et al. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem 1994; 269: 27108-27114
    PubMedGoogle Scholar
  • 64 Lachmann RH. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders. Drugs Today (Barc) 2006; 42: 29-38
    CrossrefPubMedGoogle Scholar
  • 65 Larsen SD, Wilson MW, Abe A et al. Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 2012; 53: 282-291
    CrossrefPubMedGoogle Scholar